Aberdeen Group
STRO icon

Aberdeen Group’s Sutro Biopharma STRO Stock Holding History

Aberdeen Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,939
Closed -$60.3K – 985
2025
Q3 		$60.3K Hold
6,939
– – ﹤0.01% 951
2025
Q2 		$49.5K Hold
6,939
– – ﹤0.01% 950
2025
Q1 		$45.1K Hold
6,939
– – ﹤0.01% 938
2024
Q4 		$128K Hold
6,939
– – ﹤0.01% 926
2024
Q3 		$240K Hold
6,939
– – ﹤0.01% 896
2024
Q2 		$203K Hold
6,939
– – ﹤0.01% 928
2024
Q1 		$392K Hold
6,939
– – ﹤0.01% 884
2023
Q4 		$298K Buy
+6,939
New +$220K ﹤0.01% 911

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Aberdeen Group's STRO Position: Q4 2025 in Review

Aberdeen Group sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 6,939 shares — an estimated $60.3K sold.

Aberdeen Group first reported a position in STRO in Q4 2023 and held it in 8 quarters. The position peaked at $392K in Q1 2024. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Aberdeen Group reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • Aberdeen Group sold 6,939 Sutro Biopharma shares in Q4 2025, an estimated $60.3K.
  • Aberdeen Group first reported a position in Sutro Biopharma in Q4 2023 and held it in 8 quarters.
  • Aberdeen Group's Sutro Biopharma position peaked at $392K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.